A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Vonapanitase (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors Proteon Therapeutics
- 30 Mar 2017 Status changed to not yet recruiting.
- 16 Mar 2016 New trial record
- 14 Mar 2016 The company plans to initiate this and one other phase I trial in 2016, according to a Proteon Therapeutics media release.